Segami Corporation

About Segami Corporation

Segami Corporation operates in the Software & AI space and is among the firms Bracken expects to track at SNMMI 2026.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• FierceBiotech · 2026-07-10
  Segami Corporation appoints new Chief Medical Officer ahead of pivotal trial
  The announcement comes amid tightening Mo-99 and Lu-177 supply.
• BioPharma Reporter · 2026-04-17
  Segami Corporation signs supply agreement to support late-stage trials
  Coverage notes the company's growing footprint in the radioligand therapy space.
• Reuters Health · 2026-01-24
  Segami Corporation expands cyclotron capacity to meet Lu-177 demand
  Coverage notes the company's growing footprint in the radioligand therapy space.
• Endpoints News · 2026-10-03
  Segami Corporation announces Phase II readout for lead theranostic candidate
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.
• Nuclear Medicine Today · 2026-07-10
  Segami Corporation files IND for next-generation PSMA-targeted agent
  Coverage notes the company's growing footprint in the radioligand therapy space.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.